81 related articles for article (PubMed ID: 11806625)
1. Nitrotriazole AK-2123 enhances mitomycin C activity in mice bearing multidrug-resistant tumors.
Goncharova SA; Rajewskaya TA; Konovalova NP; Kagiya TV
J Chemother; 2001 Dec; 13(6):635-40. PubMed ID: 11806625
[TBL] [Abstract][Full Text] [Related]
2. [The radiosensitizer AK-2123 enhances sensitivity of MDR-tumors to Mitomycin C].
Goncharova SA; Raevskaia TA; Konovalova NP; Kagiia VT
Vopr Onkol; 2000; 46(2):202-8. PubMed ID: 10853422
[TBL] [Abstract][Full Text] [Related]
3. In vivo characterization of P388 leukemia resistant to mitomycin C.
Rose WC; Huftalen JB; Bradner WT; Schurig JE
In Vivo; 1987; 1(1):47-52. PubMed ID: 2979764
[TBL] [Abstract][Full Text] [Related]
4. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
6. Ultralow doses of various drugs in chemotherapy of experimental tumors.
Konovalova NP
Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():45-7. PubMed ID: 12949646
[TBL] [Abstract][Full Text] [Related]
7. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of mitomycin C cytotoxicity by glutathione depletion in a multi-drug resistant mouse leukemia cell line.
Xu BH; Singh SV
Cancer Lett; 1992 Sep; 66(1):49-53. PubMed ID: 1451095
[TBL] [Abstract][Full Text] [Related]
10. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
13. Modification of radio-thermo-chemotherapy by AK-2123 and hydralazine in tumor bearing mice.
Kunugita N; Mei N; Norimura T; Kagiya TV
Indian J Exp Biol; 1996 Sep; 34(9):838-41. PubMed ID: 9014514
[TBL] [Abstract][Full Text] [Related]
14. Modulation of mitomycin C resistance by glutathione transferase inhibitor ethacrynic acid.
Singh SV; Xu BH; Maurya AK; Mian AM
Biochim Biophys Acta; 1992 Nov; 1137(3):257-63. PubMed ID: 1445927
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activities of conjugates of mitomycin C with estradiol benzoate and estradiol via glutaric acid in suspension dosage form.
Ishiki N; Onishi H; Machida Y
Biol Pharm Bull; 2002 Oct; 25(10):1373-7. PubMed ID: 12392099
[TBL] [Abstract][Full Text] [Related]
17. Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice.
Kodama N; Murata Y; Asakawa A; Inui A; Hayashi M; Sakai N; Nanba H
Nutrition; 2005 May; 21(5):624-9. PubMed ID: 15850970
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
19. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.
Marchini S; Damia G; Broggini M; Pennella G; Ripamonti M; Marsiglio A; Geroni C
Cancer Res; 2001 Mar; 61(5):1991-5. PubMed ID: 11280757
[TBL] [Abstract][Full Text] [Related]
20. Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia.
Takeuchi H; Baba H; Maehara Y; Sugimachi K; Newman RA
Cancer Chemother Pharmacol; 1996; 38(1):1-8. PubMed ID: 8603441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
